# Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

> **NCT01900522** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 76 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ITI-214 Dose A
- **DRUG:** ITI-214 Dose B
- **DRUG:** ITI-214 Dose C
- **DRUG:** ITI-214 Dose D (Elderly)
- **DRUG:** Placebo
- **DRUG:** ITI-214 Dose E
- **DRUG:** ITI-214 Dose F
- **DRUG:** ITI-214 Dose G
- **DRUG:** ITI-214 Dose H
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01900522
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 76 (ESTIMATED)
- **Why stopped:** Business Decision; No Safety or Efficacy Concerns
- **Last updated:** 2015-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900522, "Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01900522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*